$Centessa Pharmaceuticals(CNTA.US)$and$Schrodinger(SDGR.US)$will collaborate to discover therapies targeting the Orexin-2 receptor for sleep disorders. The agreement will give Centessa subsidiary Orexia Therapeutics access to Schrodinger's computing platform. The platform allows for high performance computing in order to accurately predict the effectiveness of the target of interest. The terms require Orexia to handle preclinical research activities, clinical development, and commercialization of potential candidates.
Jaguar8 : 哎哟
Trytosaveabit楼主 Jaguar8: 没有我想的那么糟糕!
Jaguar8 Trytosaveabit楼主: CYN 太糟糕了哈哈
Trytosaveabit楼主 Jaguar8: 是的!呵呵呵
Jaguar8 Trytosaveabit楼主: 我敢肯定,很多人措手不及,最后只能装袋。向外扩张是关键
查看更多评论...